MedWatch

Novo’s new hope beats rivals on blood glucose and weight reduction

Semaglutide, the major hope in Novo Nordisk's pipeline, continues to outperform rival drugs in clinical trials and a new analysis, presented on the diabetes congress EASD in Lisbon, supports the potential of the drug.

Torben Åndahl
Photo: Torben Åndahl

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles